Table 2. TB outcomes by HIV status and other factors.
| Study Group | Treatment Outcome – n (%) – | |||||
| Cured/Completed | Died before Month 8 | Failed | Unknown | Totals | ||
| HIV-uninfected | (n = 32) | 17 (53%) | 10 (31%) | 1(3%) | 4 (13%) | 32 |
| Age (years) | ≤30 | 11 (55%) | 5 (25%) | 1 (5%) | 3 (15%) | 20 |
| >30–40 | 2 (40%) | 2 (40%) | 0 | 1 (20%) | 5 | |
| >40 | 4 (57%) | 3 (43%) | 0 | 0 | 7 | |
| Sex | Female | 3 (43%) | 2 (29%) | 1 (14%) | 1 (14%) | 7 |
| Male | 14 (56%) | 8 (32%) | 0 | 3 (12%) | 25 | |
| Resistance status | Sensitive to RH | 15 (52%) | 9 (31%) | 1(3%) | 4 (14%) | 29 |
| Resistant to R or H or both | 2 (67%) | 1 (33%) | 0 | 0 | 3 | |
| Adherence in continuation phase * | (Almost/)Fully compliant | 11 (73%) | 1 (7%) | 1 (7%) | 2 (13%) | 15 |
| Missed half or more | 4 (80%) | 0 | 0 | 1 (20%) | 5 | |
| Duration of TB symptoms (months) | <3 months | 4 (36%) | 2 (18%) | 1(9%) | 4 (36%) | 11 |
| 3–6 months | 6 (43%) | 8 (57%) | 0 | 0 | 14 | |
| > 6 months | 7 (100%) | 0 | 0 | 0 | 7 | |
| BMI kg/m2 (grouped) | ≤15 | 5 (62.5%) | 2 (25%) | 0 | 1 (12%) | 8 |
| >15–18.5 | 6 (50%) | 3 (25%) | 0 | 3 (25%) | 12 | |
| >18.5 | 6 (50%) | 5 (42%) | 1(8%) | 0 | 12 | |
| Extent of disease on X-ray * | Normal | 0 | 0 | 0 | 0 | 0 |
| Minimal | 0 | 0 | 0 | 0 | 0 | |
| Moderate | 1 (33%) | 1 (33%) | 0 | 1 (33%) | 3 | |
| Severe | 15 (54%) | 9 (32%) | 1 (4%) | 3 (11%) | 28 | |
| Cavitation * | No | 1 (25%) | 2 (50%) | 0 | 1 (25%) | 4 |
| Yes | 15 (56%) | 8 (30%) | 1 (4%) | 3 (11%) | 27 | |
| Days to positivity | 7+ | 9 (64%) | 2 (14%) | 1 (7%) | 2 (14%) | 14 |
| <7 | 8 (44%) | 8 (44%) | 0 | 2 (11%) | 18 | |
| HIV infected | (n = 64) | 22 (34%) | 25 (39%) | 7 (11%) | 10 (16%) | 64 |
| Age (years) | ≤30 | 12 (43%) | 9 (32%) | 3 (11%) | 4 (14%) | 28 |
| >30–40 | 5 (19%) | 13 (50%) | 3 (12%) | 5 (19%) | 26 | |
| >40 | 5 (50%) | 3 (30%) | 1 (10%) | 1 (10%) | 10 | |
| Sex | Female | 18 (46%) | 16 (41%) | 2 (5%) | 3 (8%) | 39 |
| Male | 4 (16%) | 9 (36%) | 5 (20%) | 7 (28%) | 25 | |
| Resistance status | Sensitive to RH | 20 (33%) | 23 (38%) | 7 (12%) | 10 (17%) | 60 |
| Resistant to R or H or both | 2 (50%) | 2 (50%) | 0 | 0 | 4 | |
| Adherence in continuation phase * | (Almost/)Fully compliant | 16 (44%) | 10 (28%) | 5 (14%) | 5 (14%) | 36 |
| Missed half or more | 5 (42%) | 4 (33%) | 0 | 3 (25%) | 12 | |
| Duration of TB symptoms (months) | <3 months | 12 (30%) | 16 (40%) | 4 (10%) | 8 (20%) | 40 |
| 3–6 months | 7 (35%) | 9 (45%) | 2 (10%) | 2 (10%) | 20 | |
| > 6 months | 3 (75%) | 0 | 1 (25%) | 0 | 4 | |
| BMI kg/m2 (grouped) | ≤15 | 7 (41%) | 7 (41%) | 2 (12%) | 1 (6%) | 17 |
| 15–18.5 | 12 (35%) | 13 (38%) | 4 (12%) | 5 (15%) | 34 | |
| >18.5+ | 2 (17%) | 5 (42%) | 1 (8%) | 4 (33%) | 12 | |
| Extent of disease on X-ray * | Normal | 2 (29%) | 3 (43%) | 1 (14%) | 1 (14%) | 7 |
| Minimal | 4 (29%) | 7 (50%) | 2 (14%) | 1 (7%) | 14 | |
| Moderate | 6 (40%) | 7 (47%) | 0 | 2 (13%) | 15 | |
| Severe | 10 (37%) | 8 (30%) | 4 (15%) | 5 (19%) | 27 | |
| Cavitation * | No | 18 (37%) | 20 (41%) | 7 (14%) | 4 (8%) | 49 |
| Yes | 2 (17%) | 5 (42%) | 0 | 5 (42%) | 12 | |
| Days to positivity | 7+ | 10 (31%) | 14 (44%) | 3 (9%) | 5 (16%) | 32 |
| <7 | 12 (38%) | 11 (34%) | 4 (12%) | 5 (16%) | 32 | |